WO2003092584A3 - Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques - Google Patents

Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques Download PDF

Info

Publication number
WO2003092584A3
WO2003092584A3 PCT/US2003/012521 US0312521W WO03092584A3 WO 2003092584 A3 WO2003092584 A3 WO 2003092584A3 US 0312521 W US0312521 W US 0312521W WO 03092584 A3 WO03092584 A3 WO 03092584A3
Authority
WO
WIPO (PCT)
Prior art keywords
ctgf
growth factor
connective tissue
intraocular pressure
tissue growth
Prior art date
Application number
PCT/US2003/012521
Other languages
English (en)
Other versions
WO2003092584A2 (fr
Inventor
Debra L Fleenor
Allan Shepard
Nasreen Jacobson
Iok-Hou Pang
Abbot F Clark
Original Assignee
Alcon Inc
Debra L Fleenor
Allan Shepard
Nasreen Jacobson
Iok-Hou Pang
Abbot F Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002482789A priority Critical patent/CA2482789A1/fr
Priority to BR0309623-8A priority patent/BR0309623A/pt
Priority to US10/510,585 priority patent/US7351407B2/en
Priority to MXPA04009471A priority patent/MXPA04009471A/es
Priority to JP2004500769A priority patent/JP2005523928A/ja
Priority to KR10-2004-7016310A priority patent/KR20040104566A/ko
Application filed by Alcon Inc, Debra L Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F Clark filed Critical Alcon Inc
Priority to EP03718502A priority patent/EP1497420A4/fr
Priority to AU2003221762A priority patent/AU2003221762B2/en
Publication of WO2003092584A2 publication Critical patent/WO2003092584A2/fr
Publication of WO2003092584A3 publication Critical patent/WO2003092584A3/fr
Priority to US12/024,821 priority patent/US20080176964A1/en
Priority to US12/970,662 priority patent/US20110092523A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Abstract

La présente invention concerne une méthode destinée à réduire la pression intraoculaire et à fournir une neuroprotection à un patient en ayant besoin par administration d'une dose thérapeutiquement efficace d'au moins un agent non nucléotidique ou non protéique inhibant l'expression et/ou la signalisation du facteur de croissance du tissu conjonctif (CTGF).
PCT/US2003/012521 2002-04-30 2003-04-18 Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques WO2003092584A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR0309623-8A BR0309623A (pt) 2002-04-30 2003-04-18 Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
US10/510,585 US7351407B2 (en) 2002-04-30 2003-04-18 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MXPA04009471A MXPA04009471A (es) 2002-04-30 2003-04-18 Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
JP2004500769A JP2005523928A (ja) 2002-04-30 2003-04-18 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
KR10-2004-7016310A KR20040104566A (ko) 2002-04-30 2003-04-18 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
CA002482789A CA2482789A1 (fr) 2002-04-30 2003-04-18 Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
EP03718502A EP1497420A4 (fr) 2002-04-30 2003-04-18 Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
AU2003221762A AU2003221762B2 (en) 2002-04-30 2003-04-18 Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US12/024,821 US20080176964A1 (en) 2002-04-30 2008-02-01 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US12/970,662 US20110092523A1 (en) 2002-04-30 2010-12-16 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37660602P 2002-04-30 2002-04-30
US60/376,606 2002-04-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/024,821 Continuation US20080176964A1 (en) 2002-04-30 2008-02-01 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Publications (2)

Publication Number Publication Date
WO2003092584A2 WO2003092584A2 (fr) 2003-11-13
WO2003092584A3 true WO2003092584A3 (fr) 2004-07-01

Family

ID=29401375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/012521 WO2003092584A2 (fr) 2002-04-30 2003-04-18 Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques

Country Status (15)

Country Link
US (3) US7351407B2 (fr)
EP (2) EP2221054A1 (fr)
JP (3) JP2005523928A (fr)
KR (1) KR20040104566A (fr)
CN (1) CN1650001A (fr)
AR (1) AR039511A1 (fr)
AU (2) AU2003221762B2 (fr)
BR (1) BR0309623A (fr)
CA (1) CA2482789A1 (fr)
MX (1) MXPA04009471A (fr)
PL (1) PL378030A1 (fr)
RU (1) RU2332213C2 (fr)
TW (1) TWI288640B (fr)
WO (1) WO2003092584A2 (fr)
ZA (1) ZA200408021B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221054A1 (fr) 2002-04-30 2010-08-25 Alcon, Inc. Inhibiteurs de CDK pour abaisser la pression intraoculaire
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
CN101884789A (zh) 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
EP1742965B1 (fr) 2004-04-28 2012-10-24 Fibrogen, Inc. Traitements pour le cancer du pancreas
PL1781787T3 (pl) 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
WO2007108541A1 (fr) 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. Composition ophtalmique comprenant de la gomme de xanthane et du glucose
JP2009544734A (ja) * 2006-07-25 2009-12-17 アルコン リサーチ， リミテッド 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
EP2077829A2 (fr) * 2006-10-31 2009-07-15 Alcon Research, Ltd. Modulateurs de liaison de pai-1 utilises dans le traitement de troubles oculaires
US7807629B1 (en) 2007-06-05 2010-10-05 Alcon Research, Ltd. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
US8173668B1 (en) 2007-06-05 2012-05-08 Alcon Research, Ltd. Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma
WO2011002525A1 (fr) 2009-07-02 2011-01-06 Fibrogen, Inc. Procédés pour le traitement de la dystrophie musculaire
WO2011056234A1 (fr) 2009-11-06 2011-05-12 Fibrogen, Inc. Traitement de troubles induits par un rayonnement
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
WO2012061811A2 (fr) 2010-11-05 2012-05-10 Fibrogen, Inc. Procédé de traitement de maladies de remodelage des poumons
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
CN104781402A (zh) 2012-09-05 2015-07-15 西伦蒂斯私人股份公司 siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
WO2015132303A1 (fr) 2014-03-04 2015-09-11 Sylentis Sau Arnsi et leur utilisation dans des méthodes et des compositions pour le traitement et/ou la prévention d'affections oculaires
ES2844899T3 (es) 2015-12-10 2021-07-23 Fibrogen Inc Métodos para el tratamiento de enfermedades de las neuronas motoras
DE102018107621A1 (de) * 2018-03-29 2019-10-02 Imedos Systems GmbH Vorrichtung und Verfahren zur Untersuchung der metabolischen Autoregulation
KR20190115725A (ko) 2018-04-03 2019-10-14 한국과학기술연구원 찰콘 유도체를 포함하는 시신경 보호용 조성물
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
KR102231354B1 (ko) 2020-05-22 2021-03-24 한국과학기술연구원 찰콘 유도체를 포함하는 시신경 보호용 조성물
AU2021329413A1 (en) * 2020-08-21 2023-03-16 University Of Tennessee Research Foundation Methods of neuroprotection and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027275A1 (fr) * 2001-09-27 2003-04-03 Alcon, Inc. Inhibiteurs de la glycogene synthase kinase-3 (gsk-3) pour le traitement du glaucome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906467A (en) * 1988-03-24 1990-03-06 New York Medical College Novel, long-duration treatment for glaucoma
US7384634B2 (en) 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
AU5531599A (en) * 1998-09-01 2000-03-21 Lg Chemical Ltd. Novel cdk inhibitors having flavone structure
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
WO2000030628A2 (fr) 1998-11-20 2000-06-02 Genentech, Inc. Methode d'inhibition de l'angiogenese
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
CA2411928A1 (fr) * 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Composes pyrazole-thiazole, compositions pharmaceutiques les contenant, et leurs procedes d'utilisation pour inhiber les kinases cyclino-dependantes
WO2002013812A1 (fr) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Traitements de maladies inflammatoires
EP1343521A2 (fr) 2000-12-01 2003-09-17 Battelle Memorial Institute Procede de stabilisation de biomolecules dans des formulations liquides
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
EP2221054A1 (fr) 2002-04-30 2010-08-25 Alcon, Inc. Inhibiteurs de CDK pour abaisser la pression intraoculaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027275A1 (fr) * 2001-09-27 2003-04-03 Alcon, Inc. Inhibiteurs de la glycogene synthase kinase-3 (gsk-3) pour le traitement du glaucome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1497420A4 *

Also Published As

Publication number Publication date
PL378030A1 (pl) 2006-02-20
ZA200408021B (en) 2006-07-26
RU2332213C2 (ru) 2008-08-27
US20110092523A1 (en) 2011-04-21
CN1650001A (zh) 2005-08-03
US20080176964A1 (en) 2008-07-24
AU2008264214B2 (en) 2011-03-31
JP2010280723A (ja) 2010-12-16
EP2221054A1 (fr) 2010-08-25
JP2005523928A (ja) 2005-08-11
WO2003092584A2 (fr) 2003-11-13
US20050234075A1 (en) 2005-10-20
EP1497420A4 (fr) 2005-04-27
AU2008264214A1 (en) 2009-01-29
MXPA04009471A (es) 2005-01-25
AR039511A1 (es) 2005-02-23
RU2004134733A (ru) 2005-05-10
JP2006131643A (ja) 2006-05-25
CA2482789A1 (fr) 2003-11-13
AU2003221762B2 (en) 2008-09-25
EP1497420A2 (fr) 2005-01-19
BR0309623A (pt) 2005-02-09
AU2003221762A1 (en) 2003-11-17
US7351407B2 (en) 2008-04-01
KR20040104566A (ko) 2004-12-10
TWI288640B (en) 2007-10-21
TW200403985A (en) 2004-03-16

Similar Documents

Publication Publication Date Title
WO2003092584A3 (fr) Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2006068829A9 (fr) Agents regulant, inhibant ou modulant l'activite et/ou l'expression de la lysil oxydase (lox) et de proteases analogues a la lox, utilises en tant que moyen unique pour abaisser la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
MY138811A (en) Preventive or therapeutic agent for glaucoma
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
WO2003028802A3 (fr) Methodes et dispositifs de traitement d'une fibrillation auriculaire
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
WO2003047513A3 (fr) Methode de traitement de l'hypertension oculaire
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
WO2003079991A3 (fr) Technique d'administration d'hormone de croissance par voie pulmonaire
WO2002067971A3 (fr) Traitement de la neovasculatisation oculaire
WO2000051582A3 (fr) Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
EP1251862A4 (fr) Compositions ophthalmiques pour traiter l'hypertension oculaire
WO2006102333A3 (fr) Utilisation d'agents inhibiteurs de liaison et de signalisation du facteur de croissance de tissus conjonctifs (ctgf) via le complexe recepteur trka/p75ntr pour la prevention de troubles oculaires lies au cgtf
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
EP1482922A4 (fr) Agents pour une administration corneenne ou intrastromale pour traiter ou empecher les troubles oculaires
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
WO2009111169A3 (fr) Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2022235551A3 (fr) Agent thérapeutique à base de protéine de fusion fc pour le traitement de la pancréatite
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
WO2003101379A3 (fr) Pyranoindazoles et leur utilisation pour le traitement du glaucome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009471

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003221762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10510585

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020047016310

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2482789

Country of ref document: CA

Ref document number: 2003718502

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004500769

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038096048

Country of ref document: CN

Ref document number: 1-2004-501748

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 378030

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 3710/DELNP/2004

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004134733

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047016310

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003718502

Country of ref document: EP